MedWatch

Novo Nordisk: A lean mean money-machine

Analysis: Novo Nordisk is one of the most costly pharmaceutical companies in the world, much more costly than the size of the company warrants. Nevertheless, the growth of the company is skyrocketing.

Foto: Novo Nordisk / PR

A lean, mean money-machine.

Officially speaking, Novo Nordisk probably would not care to be associated with the slightly rewritten battle-cry of the lean, mean killing-machines of the American Marine Corps. But the Danish pharmaceutical group is just that; a lean, ruthless money-machine, that seems to generate profit no matter what and devour rivals for breakfast.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier